Novavax Inc (NVAX) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of disease...
Novavax Inc's revenue increased 64.7% year over year, from $682.2M to $1.12B.
Net income increased 334.8% over the same period, from $-187.5M to $440.3M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 7218% in total.
Operating cash flow declined 180.2% to $-244.6M.
Novavax Inc maintains a strong net profit margin of 39.2%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $692.4M+37.0% | $-366.7M | $503.6M | $-382.9M | $-537.2M | $1.66B | N/A | $-678.4M |
| Q1 FY2024 | $93.9M-86.4% | $-147.6M | $34.6M | $-144.8M | $-83.6M | $1.35B | N/A | $-867.1M |
| Q2 FY2024 | $509.3M+442.7% | $14.8M | $403.9M | $16.2M | $230.7M | $1.82B | N/A | $-431.7M |
| Q3 FY2024 | $593.9M+16.6% | $-106.5M | $427.8M | $-117.9M | $85.9M | $1.71B | N/A | $-526.4M |
| Q1 FY2025 | $666.7M+12.3% | $518.6M | $652.5M | $515.5M | $-185.5M | $1.29B | N/A | $-75.6M |
| Q2 FY2025 | $905.9M+35.9% | $625.2M | $876.5M | $616.6M | $-313.0M | $1.34B | N/A | $37.6M |
| Q3 FY2025 | $976.3M+7.8% | $422.8M | $925.4M | $438.6M | $-205.2M | $1.18B | N/A | $-156.7M |
| Q1 FY2026 | $139.5M-85.7% | $-9.5M | $108.8M | $-15.4M | $-32.4M | $1.04B | $291.0M | $-144.8M |
Balance Sheet Summary (Latest Period)
Total Assets
$1.18B
Total Liabilities
$1.30B
Total Equity
$-127.8M
Cash & Equivalents
$735.1M
Total Debt
N/A
Current Assets
$978.3M
Current Liabilities
$459.9M
Retained Earnings
$-4.57B